UFP Technologies Inc Dossier
Qualitative Analysis
Business overview
UFP Technologies, Inc. (NASDAQ: UFPT) is a leading contract development and manufacturing organization (CDMO) that designs and custom manufactures comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products. Founded in 1963 and headquartered in Newburyport, Massachusetts, the company serves as an important link in the medical device supply chain and acts as a valued outsource partner to most of the top medical device manufacturers globally. UFP Technologies specializes in single-use and single-patient devices and components used in minimally invasive surgery, robotic surgery, infection prevention, advanced wound care, wearables, orthopedic soft goods, and orthopedic implants. The company manufactures its products by converting raw materials using laminating, molding, radio frequency, and impulse welding, and fabricating manufacturing techniques. While primarily focused on the medical market, UFP also serves the aerospace and defense, automotive, consumer, electronics, and industrial markets.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Strategic shift to focus resources on high-growth, high-margin MedTech segments (such as robotic surgery, patient surfaces, and interventional devices) while allowing the legacy industrial/non-medical book of business to run off.
Expected impact: Higher consolidated gross and operating margins, and stronger alignment with secular medical outsourcing trends.
Co-investing with key customers to add new facilities in Santiago and La Romana, Dominican Republic, to support robotic surgery and safe patient handling programs.
Expected impact: Doubling of capacity on newly launched programs to meet robust forecasted customer demand.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To expand UFP's capabilities in precision thermoplastic injection-molded components for the medical device market and leverage TPI's proximity to UFP's existing operations in the Dominican Republic.
Financial impact: Adds approximately $10 million in annual revenue and $1 million in EBITDA based on historical performance.
To enhance UFP's thin film platform and Welch Fluorocarbon operation, expanding capabilities in tight tolerance thermoformed and heat-sealed polymer components for Class III implantable medical devices.
Financial impact: Strengthens high-performance film solutions portfolio and increases production scale.